ArticleBMC cancer2022
Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Two-step enucleation combined with needle electrode: a modified TURBT technique to enhance detrusor muscle detection.International urology and nephrology · 2026Article
- Bladder high-grade urothelial carcinoma in adolescent patient with failed renal transplant: a case report and literature review.International journal of surgery case reports · 2026Article
- Early Recurrence Following Complete Initial Resection Predicts Adverse Oncological Outcomes in NMIBC.Journal of clinical medicine · 2026Article
- Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.BMC cancer · 2026Article
- Article
- A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study.Frontiers in oncology · 2026Article
- Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.Asian journal of urology · 2026Review
- Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma.iScience · 2025Article
- Artificial Intelligence-Assisted Urine Cytology for Noninvasive Detection of Muscle-Invasive Urothelial Carcinoma: A Multi-Center Diagnostic Study with Prospective Validation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non-muscle-invasive bladder cancer: a retrospective, multicentre study.EClinicalMedicine · 2025Article
- Analysis of risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor in paraureteral bladder cancer.Frontiers in surgery · 2025Article
- Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence.American journal of translational research · 2024Article
- Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging.Journal of cancer research and clinical oncology · 2023Article
- Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.Clinical proteomics · 2023Article
- Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.Frontiers in medicine · 2023Article
- Impact of internet plus health education on urinary stoma caregivers in coping with care burden and stress in the era of COVID-19.Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNon-muscle invasive bladder cancer can be controlled by transurethral resection of bladder (TURB), but suffers from frequent recurrences in 60-70% of cases. Although, recurrence interval after TURB influences treatment course and prognosis, its implication and risk factors have not been fully elucidated. We evaluated the risk factors of early (within 1 yr) and late (after 1 yr) recurrence of pTa bladder cancer and clinical significance of recurrence interval on disease progression and overall survival.
methodsIn this study, pTa bladder cancer patients enrolled in prospective patient registry system of Seoul National University, SUPER-UC, were retrospectively examined to determine the clinical risk factors for recurrence and its significance regarding to recurrence interval. A total of 1067 bladder cancer patients who underwent TURB between March 20 and June 2021 were included and classified into three groups of no recurrence, early, or late recurrence to be comparatively analyzed.
resultsEarly recurrence was associated with poorer cystectomy-free survival and overall survival than late recurrence. Risk factors for early recurrence included a high number of previous TURB, tumor multiplicity, tumor location, tumor shape, incompleteness of TURB, and high tumor grade. Otherwise, late recurrence was associated with low-grade tumors with insufficient TURB depth.
conclusionPatients with risk factors for early recurrence should be closely followed up with special cautions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.